Table 2:
Treatment characteristics of elderly patients with HPV+ and HPV− OPSCC
| Variable | HPV+ (n=62) | HPV− (n=26) | All Patients (n =88) | p-valuea |
|---|---|---|---|---|
| Treatment, n (%) | 0.08 | |||
| Surgery Alone | 7 (11) | 0 (0) | 7 (8) | |
| Adjuvant RT | 15 (24) | 2 (8) | 17 (19) | |
| Adjuvant CRT | 5 (8) | 2 (8) | 7 (8) | |
| Definitive RT | 3 (5) | 4 (15) | 7 (8) | |
| Definitive CRT −Induction | 15 (24) | 10 (38) | 25 (28) | |
| Definitive CRT +Induction | 17 (27) | 8 (31) | 25 (28) | |
| Radiation Dose (Gy), n (%) | 0.06 | |||
| Median (IQR) | 66 (60–70) | 70 (68–70) | 70 (64–70) | |
| Concurrent Chemotherapy Type, n (%) | 0.10 | |||
| Cisplatin Alone | 11 (18) | 7 (27) | 18 (20) | |
| Carboplatin Alone | 11 (18) | 1 (4) | 12 (14) | |
| Cetuximab Alone | 7 (11) | 4 (15) | 11 (13) | |
| Other | 8 (13) | 8 (31) | 16 (18) | |
| TORS, n (%) | 0.40 | |||
| No | 4 (6) | 1 (4) | 5 (6) | |
| Yes | 23 (37) | 3 (12) | 26 (30) | |
| Lymph node dissection, n (%) | 0.20 | |||
| Unilateral | 17 (27) | 1 (4) | 18 (20) | |
| Bilateral | 10 (16) | 3 (12) | 13 (15) | |
| Peg tube placement, n (%) | 32 (52) | 15 (58) | 47 (53) | 0.99 |
| Prophylactic | 15 (24) | 8 (31) | 23 (26) | 0.70 |
| Reactive | 17 (27) | 7 (27) | 24 (27) | 0.70 |
| Follow-up (years) | 0.60 | |||
| Median (IQR) | 2.6 (0.9–4.7) | 1.5 (0.5–4.5) | 2.5 (0.9–4.7) |
a;
p-values relate to HPV+ versus HPV−